Literature DB >> 24239690

Neurotransmissions of antidepressant-like effects of neuromedin U-23 in mice.

Masaru Tanaka1, Gyula Telegdy2.   

Abstract

Neuromedin U (NmU) is a widely distributed and multifunctional peptide in the central nervous system and the peripheral tissues. Little is know about the mechanisms of NmU on brain functions. The rodent isoform of the NmU, NmU-23, has been shown to have anxiolytic effects involved in the β-adrenergic and cholinergic nervous systems in elevated plus maze test. NmU-23 was tested for antidepressant-like effects in modified forced swimming test (FST) in mice and furthermore, the involvement of the adrenergic, serotonergic, cholinergic, dopaminergic or gaba-ergic receptors in the antidepressant-like effect of NmU-23 was studied in modified mice FST. Mice were pretreated with a non-selective α-adrenergic receptor antagonist phenoxybenzamine, an α1/α2β-adrenergic receptor antagonist, prazosin, an α2-adrenergic receptor antagonist, yohimbine, a β-adrenergic receptor antagonist, propranolol, a mixed 5-HT1/5-HT2 serotonergic receptor antagonist, methysergide, a non-selective 5-HT2 serotonergic receptor antagonist, cyproheptadine, nonselective muscarinic acetylcholine receptor antagonist, atropine, D2,D3,D4 dopamine receptor antagonist, haloperidol or γ-aminobutyric acid subunit A (GABAA) receptor antagonist, bicuculline. NmU-23 showed the antidepressant-like effects by decreasing the immobility time and increasing the climbing and swimming time. Prazosin, haloperidol, and bicuculline prevented the effects of NmU-23 on the climbing and swimming time. Methysergide and cyproheptadine prevented the effects of NmU-23 on the immobility, swimming and climbing time. Atropine prevented the effects of NmU-23 on the climbing time. Phenoxybenzamine, yohimbine and propranolol did not change the effects of NmU-23. The results demonstrated that the antidepressant-like effect of NmU-23 is mediated, at least in part, by an interaction of the α2-adrenergic, 5-HT1-2 serotonergic, D2,D3,D4 dopamine receptor, muscarinic acetylcholine receptors and γ-aminobutyric acid subunit A (GABAA) receptor in a modified mouse FST.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Depression; Neuromedin U; Receptor

Mesh:

Substances:

Year:  2013        PMID: 24239690     DOI: 10.1016/j.bbr.2013.11.005

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  16 in total

1.  Gene expression in major depressive disorder.

Authors:  R Jansen; B W J H Penninx; V Madar; K Xia; Y Milaneschi; J J Hottenga; A R Hammerschlag; A Beekman; N van der Wee; J H Smit; A I Brooks; J Tischfield; D Posthuma; R Schoevers; G van Grootheest; G Willemsen; E J de Geus; D I Boomsma; F A Wright; F Zou; W Sun; P F Sullivan
Journal:  Mol Psychiatry       Date:  2015-05-26       Impact factor: 15.992

2.  Role of cortical alpha-2 adrenoceptors in alcohol withdrawal-induced depression and tricyclic antidepressants.

Authors:  Bruk Getachew; Sheketha R Hauser; Antonei B Csoka; Robert E Taylor; Yousef Tizabi
Journal:  Drug Alcohol Depend       Date:  2017-04-04       Impact factor: 4.492

Review 3.  Modelling the neurodevelopmental pathogenesis in neuropsychiatric disorders. Bioactive kynurenines and their analogues as neuroprotective agents-in celebration of 80th birthday of Professor Peter Riederer.

Authors:  Masaru Tanaka; Eleonóra Spekker; Ágnes Szabó; Helga Polyák; László Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2022-05-28       Impact factor: 3.850

4.  Escitalopram alters local expression of noncanonical stress-related neuropeptides in the rat brain via NPS receptor signaling.

Authors:  Aneta Piwowarczyk-Nowak; Artur Pałasz; Aleksandra Suszka-Świtek; Alessandra Della Vecchia; Aniela Grajoszek; Marek Krzystanek; John J Worthington
Journal:  Pharmacol Rep       Date:  2022-06-02       Impact factor: 3.919

5.  Modulatory effect of long-term treatment with escitalopram and clonazepam on the expression of anxiety-related neuropeptides: neuromedin U, neuropeptide S and their receptors in the rat brain.

Authors:  Aneta Piwowarczyk-Nowak; Artur Pałasz; Katarzyna Bogus; Marek Krzystanek; Iwona Błaszczyk; John J Worthington; Aniela Grajoszek
Journal:  Mol Biol Rep       Date:  2022-06-11       Impact factor: 2.742

6.  Editorial of Special Issue 'Dissecting Neurological and Neuropsychiatric Diseases: Neurodegeneration and Neuroprotection'.

Authors:  Masaru Tanaka; László Vécsei
Journal:  Int J Mol Sci       Date:  2022-06-23       Impact factor: 6.208

7.  Synaptic transmission parallels neuromodulation in a central food-intake circuit.

Authors:  Philipp Schlegel; Michael J Texada; Anton Miroschnikow; Andreas Schoofs; Sebastian Hückesfeld; Marc Peters; Casey M Schneider-Mizell; Haluk Lacin; Feng Li; Richard D Fetter; James W Truman; Albert Cardona; Michael J Pankratz
Journal:  Elife       Date:  2016-11-15       Impact factor: 8.140

8.  Regulation of motivation for food by neuromedin U in the paraventricular nucleus and the dorsal raphe nucleus.

Authors:  D L McCue; J M Kasper; J D Hommel
Journal:  Int J Obes (Lond)       Date:  2016-10-17       Impact factor: 5.095

Review 9.  Searching for Peripheral Biomarkers in Neurodegenerative Diseases: The Tryptophan-Kynurenine Metabolic Pathway.

Authors:  Nóra Török; Masaru Tanaka; László Vécsei
Journal:  Int J Mol Sci       Date:  2020-12-08       Impact factor: 5.923

Review 10.  Crosstalk between Existential Phenomenological Psychotherapy and Neurological Sciences in Mood and Anxiety Disorders.

Authors:  Lehel Balogh; Masaru Tanaka; Nóra Török; László Vécsei; Shigeru Taguchi
Journal:  Biomedicines       Date:  2021-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.